Breaking News
FONT-SIZE Plus   Neg
Share SHARE
mail  E-MAIL

Pluristem Therapeutics Moving Into New State-of-the-art GMP Facility

RELATED NEWS
Trade PSTI now with 
1/30/2013 3:09 AM ET

Pluristem Therapeutics, Inc. (PSTI: Quote), a developer of placenta-based cell therapies, Wednesday said the company has taken possession of and is moving into its new state-of-the-art GMP facility.

The facility allows for the production of mass quantities of PLacental eXpanded or PLX cells that possess the advantages of being grown utilizing Pluristem's patented 3D bioreactor technology.

The new manufacturing facility will have the capability to produce different PLX product candidates with the potential capacity of over 150,000 doses annually.

The new facility allows increasing the yield from one placenta to over ten times the yield from the previous pilot facility.

Additionally, if regulators approve more indications for clinical trials, this new facility will enable the firm to supply PLX cells to conduct these additional trials in parallel.

Zami Aberman, Chairman and CEO of Pluristem said, "We are excited to begin work in our new plant. With this new manufacturing facility, our company is capable of combining the ideal characteristics of a supply source in the placenta with a proprietary expansion technology that successfully addresses the issues of reproducibility and cost to provide high numbers of reproducible batches of the highest quality PLX cells.''

Register
To receive FREE breaking news email alerts for Pluristem Therapeutics, Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Russian Foreign Minister Sergei Lavrov warned Wednesday that Moscow would retaliate strongly if its "interests" in Ukraine are attacked. He also criticized the Ukrainian administration for relaunching its so-called anti-terrorist operation in the east of the country a day earlier. Lavrov's remarks came in an interview with Russia Today, which published excerpts of the English-language interview to While selling pressure has remained relatively subdued, stocks continue to see modest weakness in mid-day trading on Wednesday. The losses on the day come on the heels of the upward trend seen over the past several sessions. The major averages have moved roughly sideways in recent trading, lingering in the red. While a majority of Kentucky voters approve of the way Rand Paul is handling his job as Senator, the results of New York Times/Kaiser Family Foundation poll showed that voters from the Bluegrass State have a more mixed view on Paul's potential run for president in 2016.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.